» Articles » PMID: 38695241

Decoding Long Non‑coding RNAs: Friends and Foes in Cancer Development (Review)

Overview
Journal Int J Oncol
Specialty Oncology
Date 2024 May 2
PMID 38695241
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer remains a formidable adversary, challenging medical advancements with its dismal prognosis, low cure rates and high mortality rates. Within this intricate landscape, long non‑coding RNAs (lncRNAs) emerge as pivotal players, orchestrating proliferation and migration of cancer cells. Harnessing the potential of lncRNAs as therapeutic targets and prognostic markers holds immense promise. The present comprehensive review delved into the molecular mechanisms underlying the involvement of lncRNAs in the onset and progression of the top five types of cancer. By meticulously examining lncRNAs across diverse types of cancer, it also uncovered their distinctive roles, highlighting their exclusive oncogenic effects or tumor suppressor properties. Notably, certain lncRNAs demonstrate diverse functions across different cancers, confounding the conventional understanding of their roles. Furthermore, the present study identified lncRNAs exhibiting aberrant expression patterns in numerous types of cancer, presenting them as potential indicators for cancer screening and diagnosis. Conversely, a subset of lncRNAs manifests tissue‑specific expression, hinting at their specialized nature and untapped significance in diagnosing and treating specific types of cancer. The present comprehensive review not only shed light on the intricate network of lncRNAs but also paved the way for further research and clinical applications. The unraveled molecular mechanisms offer a promising avenue for targeted therapeutics and personalized medicine, combating cancer proliferation, invasion and metastasis.

Citing Articles

Targeting LINC00665/miR-199b-5p/SERPINE1 axis to inhibit trastuzumab resistance and tumorigenesis of gastric cancer via PI3K/AKt pathway.

Wang B, Liu W, Song B, Li Y, Wang Y, Tan B Noncoding RNA Res. 2024; 10:153-162.

PMID: 39399377 PMC: 11467570. DOI: 10.1016/j.ncrna.2024.07.004.

References
1.
Yang Z, Jiang S, Shang J, Jiang Y, Dai Y, Xu B . LncRNA: Shedding light on mechanisms and opportunities in fibrosis and aging. Ageing Res Rev. 2019; 52:17-31. DOI: 10.1016/j.arr.2019.04.001. View

2.
Zhang D, Fang C, Li H, Lu C, Huang J, Pan J . Long ncRNA MALAT1 promotes cell proliferation, migration, and invasion in prostate cancer via sponging miR-145. Transl Androl Urol. 2021; 10(6):2307-2319. PMC: 8261405. DOI: 10.21037/tau-20-1526. View

3.
Lang C, Dai Y, Wu Z, Yang Q, He S, Zhang X . SMAD3/SP1 complex-mediated constitutive active loop between lncRNA PCAT7 and TGF-β signaling promotes prostate cancer bone metastasis. Mol Oncol. 2020; 14(4):808-828. PMC: 7138406. DOI: 10.1002/1878-0261.12634. View

4.
Wang P, Wang Z, Zhu L, Sun Y, Castellano L, Stebbing J . A pyroptosis-related lncRNA signature in bladder cancer. Cancer Med. 2022; 12(5):6348-6364. PMC: 10028168. DOI: 10.1002/cam4.5344. View

5.
Deng X, Xiong W, Jiang X, Zhang S, Li Z, Zhou Y . LncRNA LINC00472 regulates cell stiffness and inhibits the migration and invasion of lung adenocarcinoma by binding to YBX1. Cell Death Dis. 2020; 11(11):945. PMC: 7609609. DOI: 10.1038/s41419-020-03147-9. View